webinar register page

Improving Biomarker Driven Precision Therapy in NSCLC: Less Common, More Complex: Multidisciplinary Discussion of Safety and Efficacy of TKIs for Rare Mutations in NSCLC
Biomarker based testing and precision medicine based approaches have become a standard to guide treatment decisions for metastatic non-small cell lung cancer (NSCLC) and are crucial even for early stage/resected patients. There are several barriers that prevent optimal testing for patients, but the discovery of novel molecular targets and subsequent development of targeted therapies make it critical to find ways to overcome these barriers. As treatment progresses, there is a potential to develop resistance mechanisms to commonly used targeted therapies; these new targets are identified by the integration of precision medicine.
There are more complex, rare genomic alterations in NSCLC that warrant further discussion on their impact in clinical practice based on new data. It is imperative for all members of the lung cancer treatment team (oncologists, pathologists, pharmacists, nurse practitioners, nurses, and physicians’ assistants) to understand this data and recognize the complexity of managing these patients using a precision medicine based approach in both first line and subsequent line therapies.
At this webinar, learn clinical pearls needed to attain best outcomes for your patients with these mutations in a case-based conversation with expert faculty.
• Overview of NSCLC and Transition Towards Biomarker Based Testing
• Considerations Before Treatment Initiation with RET, MET, KRASG12C, and HER-2-Directed Therapy
• Treatment Management Pearls During Therapy

This program is supported by an educational grant from Pfizer.

More detailed information including continuing education credit information can be found at: https://cme.bu.edu/NSCLCPart5

Oct 4, 2022 05:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information